The treatment of T cell lymphomas has been an innovation desert.
There has been no improvement in five-year survival rates for peripheral T cell lymphoma in over 20 years, and there is a critical need for new therapies. Outcomes with standard frontline chemotherapy are poor and the five-year survival rates remain below 30%.
Approved second line agents show limited efficacy and many patients relapse or become refractory to current drugs.
STP938 has shown anti-proliferative and pro-apoptotic effects against a range of T cell cancer cell lines and recently entered clinical development for the treatment of T cell blood cancers.
B Cell Lymphomas
Despite a number of approved second line agents and others in development, such as novel CAR-T cell therapy and bispecific antibodies, a significant percentage of patients still relapse.
STP938 has the potential to significantly impact the treatment of B cell lymphomas as monotherapy or in combination with available treatments.
Promising pre-clinical data demonstrate strong synergistic cancer-killing potential of STP938 in combination with the emerging drugs targeting the DNA damage response pathway (e.g. ATR, WEE1, CHEK1) for solid tumours.
STP938 has the potential to treat autoimmune conditions such as graft versus host disease.
The goal in the development of new drugs for autoimmune diseases is to look for agents with novel mechanisms of action that provide specific modulation of the immune system rather than global immunosuppression.
Step Pharma’s CTPS1 inhibitors have the potential to achieve selective modulation of activated lymphocytes.
15 rue Louis et Auguste Lumière
Technoparc du Pays-de-Gex